ATE288273T1 - Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen - Google Patents

Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen

Info

Publication number
ATE288273T1
ATE288273T1 AT98943457T AT98943457T ATE288273T1 AT E288273 T1 ATE288273 T1 AT E288273T1 AT 98943457 T AT98943457 T AT 98943457T AT 98943457 T AT98943457 T AT 98943457T AT E288273 T1 ATE288273 T1 AT E288273T1
Authority
AT
Austria
Prior art keywords
uridine
diphosphate
analogues
treatment
lung diseases
Prior art date
Application number
AT98943457T
Other languages
English (en)
Inventor
Richard C Boucher Jr
Sammy Ray Shaver
William Pendergast
Benjamin Yerxa
Janet L Rideout
Robert Dougherty
Dallas Croom
Original Assignee
Univ North Carolina
Inspire Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Inspire Pharmaceuticals filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE288273T1 publication Critical patent/ATE288273T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98943457T 1997-08-29 1998-08-28 Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen ATE288273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5706497P 1997-08-29 1997-08-29
PCT/US1998/017894 WO1999009998A1 (en) 1997-08-29 1998-08-28 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases

Publications (1)

Publication Number Publication Date
ATE288273T1 true ATE288273T1 (de) 2005-02-15

Family

ID=22008285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943457T ATE288273T1 (de) 1997-08-29 1998-08-28 Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen

Country Status (14)

Country Link
US (3) US6143279A (de)
EP (1) EP1011688B1 (de)
JP (1) JP2001513568A (de)
KR (1) KR20010023359A (de)
CN (1) CN1268056A (de)
AR (1) AR013454A1 (de)
AT (1) ATE288273T1 (de)
AU (1) AU9124998A (de)
BR (1) BR9811612A (de)
CA (1) CA2300146A1 (de)
DE (1) DE69828892D1 (de)
ID (1) ID29198A (de)
WO (1) WO1999009998A1 (de)
ZA (1) ZA987847B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
EP1012154B1 (de) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
AU9124998A (en) * 1997-08-29 1999-03-16 Inspire Pharmaceuticals Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases
JP2002533110A (ja) * 1998-12-23 2002-10-08 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｇタンパク質共役レセプターを使用した目的とする遺伝子の導入
AU3612600A (en) * 1999-02-26 2000-09-14 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
AU782966B2 (en) * 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
EP1282707A2 (de) * 2000-05-11 2003-02-12 Bayer Aktiengesellschaft Regulation des menschlichen p2y-ähnlichen g-protein gekoppelten rezeptors
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
WO2003024980A1 (fr) * 2001-09-14 2003-03-27 Universite De Liege Preparation de composes organiques triphosphoryles eventuellement marques au phosphore 32 ou au phosphore 33
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
WO2003039473A2 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
AU2003217863B9 (en) * 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
JP2006505585A (ja) * 2002-10-18 2006-02-16 モリケム メディシンズ， インコーポレイテッド ランチビオティクスで眼乾燥症を処置する方法
EP1608410A2 (de) * 2003-03-31 2005-12-28 University of Iowa Research Foundation Pharmazeutische therapie und gentherapie von krankheiten, die mit dem epithelialen natriumkanal assoziert sind
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1753445A4 (de) * 2004-05-06 2009-05-20 Molichem Medicines Inc Behandlung von augenerkrankungen und augenleiden mit lantibiotischen zusammensetzungen
CA2565457A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
US8618074B2 (en) 2007-03-15 2013-12-31 Board Of Regents Of The University Of Texas System GPCR enhanced neuroprotection to treat brain injury
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2640485T3 (es) 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
CN107353316B (zh) 2011-09-30 2020-08-18 塔夫斯大学 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
US9913855B2 (en) 2012-09-28 2018-03-13 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
BR112015014349A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
EP3449925B1 (de) * 2013-03-13 2021-08-04 Tufts University Uridinnukleosidderivate, zusammensetzungen und verfahren zur verwendung
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR20210077946A (ko) * 2019-12-18 2021-06-28 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (de) * 1962-10-30
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
JPS5415073B2 (de) * 1972-09-14 1979-06-12
US4058601A (en) * 1974-07-11 1977-11-15 Chugai Seiyaku Kabushiki Kaisha Method for treating alcoholism
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (de) * 1991-06-05 1992-12-09 Synthelabo Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
CN1262556C (zh) * 1997-02-06 2006-07-05 印斯拜尔药品股份有限公司 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
AU9124998A (en) * 1997-08-29 1999-03-16 Inspire Pharmaceuticals Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases

Also Published As

Publication number Publication date
EP1011688B1 (de) 2005-02-02
CN1268056A (zh) 2000-09-27
KR20010023359A (ko) 2001-03-26
US6451288B1 (en) 2002-09-17
AR013454A1 (es) 2000-12-27
JP2001513568A (ja) 2001-09-04
BR9811612A (pt) 2000-08-08
ZA987847B (en) 1999-06-28
DE69828892D1 (de) 2005-03-10
US6143279A (en) 2000-11-07
CA2300146A1 (en) 1999-03-04
US6022527A (en) 2000-02-08
EP1011688A1 (de) 2000-06-28
AU9124998A (en) 1999-03-16
WO1999009998A1 (en) 1999-03-04
ID29198A (id) 2001-08-09

Similar Documents

Publication Publication Date Title
ATE288273T1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
DE69600307T2 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
ATA33697A (de) Faktor x-deletionsmutanten und analoge davon
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59500393D1 (de) Verfahren zur Herstellung von Cyclopropylalkylketonen und 4,5-Dihydroalkylfuranen
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69922440D1 (de) Verfahren und Zwischenprodukte zur Herstellung von 2,3-Pyridindicarboxylatderivaten
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids
DE69636790D1 (de) Interferon-beta gegen knochenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties